Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + fluorouracil + methotrexate + prednisone + thiotepa + vinblastine + vincristine
- Development stage
- Unknown
- Lead developer
- Baxter
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A multi-agent chemotherapy regimen combining eight different antineoplastic agents. This combination includes alkylating agents (cyclophosphamide, thiotepa), anthracyclines (doxorubicin), antimetabolites (fluorouracil, methotrexate), vinca alkaloids (vinblastine, vincristine), and a corticosteroid (prednisone). This comprehensive approach targets cancer cells through multiple mechanisms of action simultaneously, potentially improving efficacy in treating breast cancer, particularly in patients with node-positive disease.
02
Targets
DNADHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)Microtubule
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + fluorouracil + methotrexate + prednisone + thiotepa + vinblastine + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + fluorouracil + methotrexate + prednisone + thiotepa + vinblastine + vincristine.